130 related articles for article (PubMed ID: 17288520)
21. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
Bertenshaw GP; Yip P; Seshaiah P; Zhao J; Chen TH; Wiggins WS; Mapes JP; Mansfield BC
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2872-81. PubMed ID: 18843033
[TBL] [Abstract][Full Text] [Related]
22. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers.
Williams TI; Toups KL; Saggese DA; Kalli KR; Cliby WA; Muddiman DC
J Proteome Res; 2007 Aug; 6(8):2936-62. PubMed ID: 17583933
[TBL] [Abstract][Full Text] [Related]
23. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
24. On consensus biomarker selection.
Dutkowski J; Gambin A
BMC Bioinformatics; 2007 May; 8 Suppl 5(Suppl 5):S5. PubMed ID: 17570864
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers for lung cancer: clinical uses.
Greenberg AK; Lee MS
Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
27. Current proteomic analysis and post-translational modifications of biomarkers in human lung cancer materials.
Sinchaikul S; Hongsachart P; Sriyam S; Tantipaiboonwong P; Phutrakul S; Chen ST
Chang Gung Med J; 2008; 31(5):417-30. PubMed ID: 19097588
[TBL] [Abstract][Full Text] [Related]
28. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies.
Kulasingam V; Diamandis EP
Nat Clin Pract Oncol; 2008 Oct; 5(10):588-99. PubMed ID: 18695711
[TBL] [Abstract][Full Text] [Related]
29. Inhibin as a diagnostic marker for ovarian cancer.
Robertson DM; Pruysers E; Jobling T
Cancer Lett; 2007 Apr; 249(1):14-7. PubMed ID: 17320281
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer biomarkers for molecular biosensors and translational medicine.
Suh KS; Park SW; Castro A; Patel H; Blake P; Liang M; Goy A
Expert Rev Mol Diagn; 2010 Nov; 10(8):1069-83. PubMed ID: 21080822
[TBL] [Abstract][Full Text] [Related]
31. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
[TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer: biomarker proteomic diagnosis in progress.
Zhang Y; Guo B; Bi R
Appl Biochem Biotechnol; 2012 Oct; 168(4):910-6. PubMed ID: 22945560
[TBL] [Abstract][Full Text] [Related]
33. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins.
Li B; An HJ; Kirmiz C; Lebrilla CB; Lam KS; Miyamoto S
J Proteome Res; 2008 Sep; 7(9):3776-88. PubMed ID: 18642944
[TBL] [Abstract][Full Text] [Related]
34. [Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women].
Markova D; Milchev N; Batashki I; Uchikov A
Akush Ginekol (Sofiia); 2008; 47(1):16-9. PubMed ID: 18642569
[TBL] [Abstract][Full Text] [Related]
35. Profiling studies in ovarian cancer: a review.
Fehrmann RS; Li XY; van der Zee AG; de Jong S; Te Meerman GJ; de Vries EG; Crijns AP
Oncologist; 2007 Aug; 12(8):960-6. PubMed ID: 17766655
[TBL] [Abstract][Full Text] [Related]
36. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
37. Proteomics: new technologies and clinical applications.
Latterich M; Abramovitz M; Leyland-Jones B
Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
[TBL] [Abstract][Full Text] [Related]
38. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
39. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
Bharti A; Ma PC; Salgia R
Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
[TBL] [Abstract][Full Text] [Related]
40. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.
Gadducci A; Cosio S; Tana R; Genazzani AR
Crit Rev Oncol Hematol; 2009 Jan; 69(1):12-27. PubMed ID: 18595727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
